EXTRAMURAL RESEARCH FACILITIES CONSTRUCTION

描述(由申请人提供)： 这项申请要求3,221,187美元的配套资金，以完成戴维斯大楼第二层和第三层的31,000个ASF/45,400个GSF。完工后的空间将容纳新创建的自动免疫和免疫疗法中心，该中心将与可能是美国最大的致力于临床护理和1型(自身免疫型)糖尿病研究的1型糖尿病中心密切合作，占据大楼剩余的63,100总面积。 我们对自身免疫性疾病和免疫疗法的理解上的一场革命，以及在这两个领域处于前沿的教师队伍，导致了这一提议。1型糖尿病是一种慢性自身免疫性疾病，一种常见的疾病预测范式可应用于器官特异性和非器官特异性自身免疫，这种自身免疫性疾病可能更相似而不是不同，主要不同之处在于自身免疫的靶标是自身抗原。因此，分享自身免疫的想法、设备、试剂、会议和开创性的前瞻性研究将带来巨大的好处。完工后，空荡荡的空间将容纳致力于基础和临床研究的教职员工和他们的实验室，他们的研究项目包括1型糖尿病、移植免疫生物学、临床免疫学和风湿病。最初的教员将在儿科和成人内分泌学、遗传学、预防医学、细胞和结构生物学、免疫学、风湿学、临床免疫学、自身免疫性肺病和胃肠病方面进行预约，不仅将为校园提供资源，也将为国家/国际科学家提供资源。尽管目前的地理位置分散，但该项目的教职员工已经建立了许多密切的联系。在过去的四年里，他们成功地竞争了美国国立卫生研究院糖尿病内分泌研究中心、自体免疫卓越中心、自体免疫预防中心、胰岛细胞资源中心和贝塔生物联盟中心。有机会创建跨学科项目，在这些项目中，对1型糖尿病和乳糜泻等疾病的治疗不是作为内分泌或胃肠道疾病，而是从免疫学根源入手。此外，类风湿性关节炎等疾病将受益于1型糖尿病研究中已经开发的疾病预测范例和检测技术。最后，我们的教员致力于培训下一代基础和临床研究人员，这些努力也严重依赖于共享设施。科罗拉多大学董事会已批准位于菲茨西蒙斯的4层加部分地下室108,500 GSF Barbara Davis中心作为科罗拉多大学医学院的组成部分。

DESCRIPTION (provided by applicant): This application requests $3,221,187 of matching funds to finish 31,000 asf/45,400 gsf on the second and third floors of the Davis building. The finished space will house newly created Autoimmunity and Immunotherapeutics Center that will closely collaborate with what is probably the largest Type 1 diabetes center in the country devoted to both clinical care and Type 1 (the autoimmune form) diabetes research occupying the remaining 63,100 gross square feet of the building. A revolution in our understanding of both autoimmune diseases and immunotherapeutics and a faculty at the forefront of both of these fields, has led to this proposal. Type 1 diabetes is a chronic autoimmune disorder and a common paradigm of disease prediction can be applied to both organ specific and non-organ specific autoimmunity, and such autoimmune disorders are probably more similar than different, differing primarily in the autoantigens that are the target of autoimmunity. Thus, there is a tremendous benefit in sharing ideas, equipment, reagents, conferences and pioneering prospective studies of autoimmunity. The shelled space when finished will house faculty and their laboratories devoted to basic and clinical research with research programs in type 1 diabetes, transplantation immunobiology, clinical immunology and rheumatology. Initial faculty will have appointments in pediatric and adult endocrinology, genetics, preventive medicine, cell and structural biology, immunology, rheumatology, clinical immunology, autoimmune pulmonary and gastroenterology disorders and will be a resource not only for the campus but also for national/international scientists. The nidus of the program faculty has already developed many close ties despite current geographic dispersion. They have successfully competed in the past four years for a National Institutes of Health Diabetes Endocrine Research Center, an Autoimmunity Center of Excellence, an Autoimmunity Prevention Center, an Islet Cell Resource Center and a Beta-biology consortium Center. There is an opportunity to create interdisciplinary programs where therapy of disorders such as type 1 diabetes and celiac disease are approached not as an endocrine or gastrointestinal disorder but at their immunologic root. In addition disorders such as rheumatoid arthritis will benefit from the disease prediction paradigms and assay technology already developed in studies of type 1 diabetes. Finally, our faculty is dedicated to training of the next generation of basic and clinical researchers and these efforts also are critically dependent upon shared facilities. The University of Colorado Board of Regents has approved the 4 story plus partial basement 108,500 gsf Barbara Davis Center at Fitzsimons as an integral component of the University of Colorado School of Medicine.